A Cluster-Randomized Study to Examine National Characteristics and Outcome Measures of GERD Patients Utilizing the PPI Acid Suppression Symptom (PASS) Test for Response [EncomPASS].

Trial Profile

A Cluster-Randomized Study to Examine National Characteristics and Outcome Measures of GERD Patients Utilizing the PPI Acid Suppression Symptom (PASS) Test for Response [EncomPASS].

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Sep 2010

At a glance

  • Drugs Esomeprazole (Primary)
  • Indications Gastro-oesophageal reflux
  • Focus Therapeutic Use
  • Acronyms EncomPASS
  • Sponsors AstraZeneca
  • Most Recent Events

    • 04 Jun 2009 Effects on persistent GERD symptoms reported at DDW 2009.
    • 04 Jun 2009 Effects on sleep disturbance were reported at DDW 2009.
    • 30 May 2009 Results from a cost-utility analysis using data from this study were reported in an abstract at Digestive Disease Week 2009, 30 May 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top